Table 2.

Comparison between the Three Studied Groups According to Clinical Data

	Group I (n= 30)		Group IIA (n= 26)		Group IIB (n= 25)		Test of sig.	p
	No.	%	No.	%	No.	%
PVT
No	18	60	24	92.3	25	100	χ2=16.891*	<0.001*
Yes	12	40	2	7.7	0	0
Sig.bet.Grps	p1=0.005*, p2<0.001*, FEp3=0.490
Ascites
No	23	76.7	20	76.9	25	100	χ2=8.221*	0.016*
Yes	7	23.3	6	23.1	0	0
Sig.bet.Grps	p1=1.000, FEp2=0.012*, FEp3=0.023*
Smoking
No	5	16.7	16	61.5	21	84	χ2=26.203*	<0.001*
Yes	25	83.3	10	38.5	4	16
Sig.bet.Grps	p1=0.001*,p2<0.001*, p3=0.072
Hypertension
No	14	46.7	12	46.2	18	72	χ2= 4.556	0.102
Yes	16	53.3	14	53.8	7	28
DAA
No	22	73.3	18	69.2	15	60	χ2= 1.143	0.565
Yes	8	26.7	8	30.8	10	40
Child-Pugh Score
A	21	70	20	76.9			χ2= 3.076	MCp=
B	7	23.3	2	7.7				0.248
C	2	6.7	4	15.4
FIB 4
Min. – Max.	1.31 – 22.99		1.17 – 14.87		0.71 – 2.43		H=45.020*	<0.001*
Mean ± SD.	5.65 ± 5.06		4.38 ± 4.28		1.20 ± 0.39
Sig.bet.Grps	p1=00.98, p2<0.001*, p3<0.001*

χ², Chi square test; MC, Monte Carlo test; H, H for Kruskal Wallis test, Pairwise comparison bet. each 2 groups was done using Post Hoc Test (Dunn's for multiple comparisons test); p, p value for comparing between the studied groups; p₁, p value for comparing between Group I and Group IIA; p₂, p value for comparing between Group I and Group IIB; p₃, p value for comparing between Group IIA and Group IIB; *, Statistically significant at p ≤ 0.05; Group I, patients with HCC complicating chronic HCV infected; Group ПA, patients with chronic hepatitis C infection with cirrhosis (HCV); Group ПB, patients with chronic hepatitis C infection without cirrhosis (HCV) ; PVT, Portal Vein Thrombosis; DAA, Direct Acting Anti-virals